Hemab Therapeutics Unveils New Data on HMB-002 and HMB-003 at ISTH 2026 Congress

Hemab Therapeutics has introduced significant advancements in the treatment of bleeding disorders, showcasing promising data for HMB-002 and revealing HMB-003 at the ISTH 2026 Congress. These developments aim to address long-standing challenges in managing conditions like Von Willebrand Disease and heavy menstrual bleeding.